Apellis Pharmaceuticals

Apellis Pharmaceuticals is a commercial-stage biopharmaceutical enterprise focused on discovering and developing targeted therapies that regulate the complement cascade at the central C3 protein. The company commercializes Empaveli for paroxysmal nocturnal hemoglobinuria alongside Syfovre, an FDA-approved intravitreal therapy that slows lesion progression in geographic atrophy secondary to age-related macular degeneration. By controlling excessive complement activation, Apellis Pharmaceuticals protects tissues and prevents vision loss.